The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...

Myasthenia gravis is an autoimmune disorder in which antibodies disrupt the communication between nerves and muscles, ...

Recent findings regarding interferon and Janus kinase inhibition may hold clues to improving outcomes in patients with ...

We recently published a list of Smart Money Ratings For 20 Most Undervalued Stocks. In this article, we are going to take a ...

Immunovant, Inc. (NASDAQ: IMVT) has announced significant changes to its leadership team and an expansion of its developmental initiatives with the addition of two new indications for its IMVT-1402 ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might push for higher standards in the review of medicines under his division's ...

We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to ...

Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage immunology company that is focused on developing therapies for patients with autoimmune diseases. The company is a leader in anti-FcRn technology ...

Immunovant announced that potentially registrational trials for IMVT-1402 are currently enrolling patients in four indications: myasthenia gravis (MG), chronic inflammatory demyelinating ...

J.B. Hunt Transport Services, Inc. engages in the provision of logistics solutions. It operates through the following segments: Intermodal (JBI), Dedicated Contract Services (DCS), Integrated ...

Detailed price information for Alx Oncology Holdings Inc (ALXO-Q) from The Globe and Mail including charting and trades.

Biohaven secures up to $600M investment from Oberland Capital via non-dilutive note purchase agreement. Funding to support clinical trials, commercialization ahead of potential FDA approval of ...